Patents by Inventor Christine Rettew Fisher

Christine Rettew Fisher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and Administration of Chimeric Glycoprotein Lyssavirus Vaccines for Coverage Against Rabies
    Publication number: 20230126396
    Abstract: The present disclosure is directed towards chimeric glycoproteins wherein the clip region, a core region, a flap region, and a transmembrane and cytoplasmic domain are defined by starting from the amino terminus of the protein, these domains are comprised of the following amino acid residue ranges: clip, 1 through 40 to 60; core, 40 to 60 through 249 to 281; flap, 249 to 281 through 419 to 459; the transmembrane domain is comprised of amino acids 460 through 480, and the remaining amino acids 481 through 525 comprise the cytoplasmic domain; and wherein the clip, core, flap, transmembrane, and cytoplasmic domain comprise a chimeric combination of at least two lyssavirus, wherein the chimeric glycoprotein is advantageously inserted into a rabies-based vaccine vector.
    Type: Application
    Filed: October 13, 2022
    Publication date: April 27, 2023
    Inventors: Matthias Schnell, Christine Rettew Fisher, Christoph Wirblich, Gene Tan
  • Compositions and administration of chimeric glycoprotein lyssavirus vaccines for coverage against rabies
    Patent number: 11484586
    Abstract: The present disclosure is directed towards chimeric glycoproteins wherein the clip region, a core region, a flap region, and a transmembrane and cytoplasmic domain are defined by starting from the amino terminus of the protein, these domains are comprised of the following amino acid residue ranges: clip, 1 through 40 to 60; core, 40 to 60 through 249 to 281; flap, 249 to 281 through 419 to 459; the transmembrane domain is comprised of amino acids 460 through 480, and the remaining amino acids 481 through 525 comprise the cytoplasmic domain; and wherein the clip, core, flap, transmembrane, and cytoplasmic domain comprise a chimeric combination of at least two lyssavirus, wherein the chimeric glycoprotein is advantageously inserted into a rabies-based vaccine vector.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: November 1, 2022
    Assignees: Thomas Jefferson University, ICAHN School of Medicine at Mount Sinai
    Inventors: Matthias Schnell, Christine Rettew Fisher, Christoph Wirblich, Gene Tan
  • COMPOSITIONS AND ADMINISTRATION OF CHIMERIC GLYCOPROTEIN LYSSAVIRUS VACCINES FOR COVERAGE AGAINST RABIES
    Publication number: 20210145959
    Abstract: The present disclosure is directed towards chimeric glycoproteins wherein the clip region, a core region, a flap region, and a transmembrane and cytoplasmic domain are defined by starting from the amino terminus of the protein, these domains are comprised of the following amino acid residue ranges: clip, 1 through 40 to 60; core, 40 to 60 through 249 to 281; flap, 249 to 281 through 419 to 459; the transmembrane domain is comprised of amino acids 460 through 480, and the remaining amino acids 481 through 525 comprise the cytoplasmic domain; and wherein the clip, core, flap, transmembrane, and cytoplasmic domain comprise a chimeric combination of at least two lyssavirus, wherein the chimeric glycoprotein is advantageously inserted into a rabies-based vaccine vector.
    Type: Application
    Filed: June 13, 2018
    Publication date: May 20, 2021
    Applicants: Thomas Jefferson University, ICAHN School of Medicine at Mount Sinai
    Inventors: Schnell Matthias, Christine Rettew Fisher, Christoph Wirblich, Gene Tan